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Selective Estrogen Receptor Modulators (SERMs) are synthetic compounds that bind with varying affinity to
estrogen receptor-alpha and -beta, and for this reason, they are currently used to treat various diseases,
including breast cancer and osteoporosis. Due to their antagonistic activity in the uterus, methyl-piperidino-
pyrazole (MPP), raloxifene, and ICI 182,780 might be used to treat endometrial cancer in women. The goal
of this research was, thus, to discern the in vitro and in vivo effects of the SERMs, MPP, raloxifene, and ICI
182,780, along with 17beta-estradiol, on endometrial carcinoma cells in culture and on murine uterine
tissue. The SERMs, MPP and raloxifene, at 1 nM concentrations in vitro, induced significant apoptosis in
both endometrial cancer and normal uterine cells when compared to vehicle control alone (P </ 0.0001).
These compounds increased uterine wet weight when injected intra-peritoneally (I.P.) (25 to 150 ug doses)
into ovariectomized CF1 mice. In addition, our in vivo studies demonstrated that both MPP and raloxifene
induce apoptosis in uterine stromal cells rather than luminal epithelium, and cause proliferation of the
luminal epithelium. In order to better understand the effect of these SERMs on gene expression in the
uterus, microarray experiments were performed by using Affymetrix Mouse Genome 430 2.0 short oligomer
arrays. The SERMs, MPP, raloxifene, and ICI 182,780 were employed either alone (50 ug doses) or in
combination with 17beta-estradiol (low 1 ug or high 50 ug dose) along with a DMSO vehicle control, which
resulted in nine treatment groups. These nine groups organized into two main clusters with MPP,
raloxifene, and the high dose of 17beta-estradiol clustering together. Another cluster included the low dose
of 17beta-estradiol, ICI + 17beta-estradiol, ICI alone, MPP + 17beta-estradiol, and raloxifene + 17beta-
estradiol. Interestingly, the ICI presumably caused competitive antagonism with the 17beta-estradiol
treatment and suppressed genes involved in mitosis and cytokinesis. These results provide a framework for
the pro-apoptotic, proliferative, and genetic actions of MPP, raloxifene, and ICI 182,780 in the uterus.
